Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma

Omid Hamid • 12 Nov 2021
SITC 2021
Melanoma Skin Cancer Antibodies Durvalumab Tebentafusp Tremelimumab

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the results of a Phase Ib study evaluating tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma (NCT02535078). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Omid Hamid

1:54
C-144-01: lifileucel in mucosal melanoma pretreated with ICIs
Omid Hamid • 23 Oct 2023
2:31
The future of BiTEs and ImmTACs in melanoma and beyond
Omid Hamid • 23 Oct 2023
1:55
The benefits of tebentafusp in uveal melanoma
Omid Hamid • 23 Oct 2023
2:01
Elucidating biomarkers of response in the RELATIVITY-047 trial
Omid Hamid • 23 Oct 2023

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals